EKF Diagnostics said Wednesday it expected adjusted earnings (EBITDA) would be 'comfortably ahead' of market expectations as it continued to make significant progress on in delivering on its strategy. 'The company announces that adjusted EBITDA for the year ended 31 December 2018 is expected to be comfortably ahead of market expectations,' EKF said. Cash generation in the second half had been 'very strong' with net cash at the end of the year of £9.4m, up from £7.0m last year, following the £3.1m investment in Renalytix AI and share buybacks of almost £0.9m, the company said. The outlook in 2019 was 'positive' as the company aimed to benefit from the groundwork laid in 2018, including a full-year contribution from the OEM contract with McKesson-Surgical for the distribution of Diaspect Tm in the US and the enzyme business with Oragenics. At 8:33am: (LON:EKF) EKF Diagnostics Holdings PLC share price was +2.25p at 33.55p
Sign up to our
Subscribe to the latest investing news by entering your email address below
You can opt out at any time.
For five days a week you will get
- The latest company news
- Insight into investment trends
- Round-up of director's buys and sells
- Articles from Shares magazine
Plus more useful investment content and occasional promotional offers.
UK 350 Risers and Fallers
Tweets not available.